Mesenchymal Stem Cells-Derived Exosomes is under clinical development by CellTex Therapeutics and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Mesenchymal Stem Cells-Derived Exosomes’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Mesenchymal Stem Cells-Derived Exosomes overview

The therapeutic candidate is under development for the treatment of Alzheimer's disease. The drug candidate comprises exosomes derived from autologous mesenchymal stem cells. It is being developed based on A-1 Exosomes platform.

CellTex Therapeutics overview

CellTex Therapeutics (CellTex) is an adult stem cell laboratory that provides stem cell banking and stem cell infusion services to their clients. It operates a bank to store adult stem cells for medical treatments. CellTex is headquartered in Houston, Texas, the US.

For a complete picture of Mesenchymal Stem Cells-Derived Exosomes’s drug-specific PTSR and LoA scores, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.